With 96 Percent Opt-In Rate, Actos Bladder Cancer Settlement Gets $2.37B Payment

(September 16, 2015, 10:44 AM EDT) -- DEERFIELD, Ill. — Takeda Pharmaceutical Co. Ltd. on Sept. 12 announced that more than 96 percent of eligible claimants have opted in to the $2.4 billion Actos bladder cancer settlement, triggering a $2.37 billion payment by the company into a settlement fund.

Takeda announced in April that it agreed to pay up to $2.4 billion to settle about 9,000 federal and state court cases in which plaintiffs allege that the diabetes drug caused bladder cancer.

The settlement requires a participation rate of 95 percent of eligible...
To view the full article, register now.